FDA Brief

Warning letters Drugs

FDA warning letter to

Inopak, Ltd.

High riskIssued Dec 15, 2023Posted Jan 2, 2024Division of Pharmaceutical Quality Operations I

Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

What happened

FDA inspected Inopak's drug manufacturing facility in Ringwood, New Jersey, from July 24 to August 3, 2023. FDA found that Inopak's quality unit did not adequately review contract manufacturer records to ensure methanol testing and ethanol impurity limits before accepting components, and did not investigate leaking drug product. FDA also found Inopak stopped ongoing stability testing on January 6, 2023, while product was labeled with expiration dates through July 29, 2024.

What FDA found

  1. The quality unit did not adequately review contract manufacturer records to ensure methanol testing was done before components were accepted.

    21 CFR 211.22(a) and 211.22(d)
  2. The firm did not ensure its ethanol met acceptable levels for known impurities such as benzene, acetaldehyde, and acetal.

    21 CFR 211.22(a) and 211.22(d)
  3. The firm did not adequately investigate leaking drug product from its contract manufacturer or communicate with the contractor to investigate.

    21 CFR 211.22(a) and 211.22(d)
  4. The firm failed to maintain an ongoing stability program to support expiration dates on distributed drug products.

    21 CFR 211.137(a)

What FDA wants

FDA asks Inopak to respond in writing within 15 working days with a quality-unit assessment and remediation plan, an investigation and CMO communication for the leaking product with destruction documentation, and a stability plan and U.S. product action plan including possible customer notifications and recalls. FDA also says to notify it before resuming drug manufacturing.

Who should pay attention

  • brands and retailers selling Inopak private-label hand sanitizer
  • companies relying on contract manufacturers for OTC drugs
  • quality units managing supplier and contract-manufacturer oversight

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk